The Salmeterol Anomaly and the Need for a Urine Threshold

The Salmeterol Anomaly and the Need for a Urine Threshold / Glenn A. Jacobson, Morten Hostrup. - (Drug Testing and Analysis (2020) 20 April).
- PMID: 32314556.
- DOI: 10.1002/dta.2810
_________________________________________________

Abstract

Salmeterol is a long acting beta2‐agonist (LABA) widely used for treatment of airways disease. There is evidence that beta2‐agonists, including salmeterol, have the potential for performance enhancing effects when delivered at supratherapeutic doses. For this reason, all beta2‐agonists are currently on the Prohibited List issued by the World Anti‐Doping Agency (WADA) regardless of dosing route with some exemptions for inhaled salbutamol, formoterol, and salmeterol when used at therapeutic inhaled doses. For 2020, salmeterol use is permitted up to a therapeutic dosing threshold of 200 μg daily, but unlike salbutamol and formoterol, there is an anomaly; currently there is no urine threshold to control for supratherapeutic dosing beyond this dosing threshold. Salmeterol, however, is reportable as an Adverse Analytical Finding (AAF) at levels above 10 ng/ml. Complicating matters is that following inhalation, salmeterol parent drug is present at relatively low levels compared to other beta2‐agonists due to rapid metabolism to the metabolite, alpha‐hydroxysalmeterol, which is typically present at higher levels than parent drug. Moreover, peak parent drug levels following permitted therapeutic dosing are below the minimum required performance level (MRPL) of 10 ng/ml for salmeterol (50% of the MRPL that analytical laboratories are required to meet for non‐threshold beta2‐agonists), hence the presence of salmeterol may be unreported. For consistency, a urine threshold should be introduced for salmeterol as matter of priority, to balance the needs of athletes that use salmeterol therapeutically up to the agreed dosing threshold, with the need to control supratherapeutic dosing for doping intentions and athlete harm minimisation.

Parameters:

Science
Review
Date:
20 April 2020
People
Hostrup, Morten
Jacobson, Glen A.
Country
Australia
Denmark
Language
English
ADRV
Adverse Analytical Finding / presence
Other organisations
Københavns Universitet - University of Copenhagen (UCPH)
University of Tasmania (UTAS)
Analytical aspects
Half-life / excretion time of substance
Threshold for exogenous substances
Doping classes
S3. Beta-2 Agonists
Substances
Salmeterol
Medical terms
Legitimate Medical Treatment
Document category
Abstract
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin